NZ: Cannasouth receives GMP licence to manufacture medicines

Cannasouth has received its Licence to Manufacture Medicines to produce dried cannabis flower (to the globally recognized GMP standard) at its cultivation facility.

To obtain this license, Cannasouth had to demonstrate compliance with the New Zealand Code of Good Manufacturing Practice (GMP) for the Manufacture and Distribution of Therapeutic Goods. GMP is the highest quality standard possible.

CEO Mark Lucas says, "Achieving the globally recognized GMP standard for our commercial scale facility opens doors to high-value markets worldwide while also enabling us to launch products in New

"We are seeing exponential growth in demand for GMP flower in Australia and Europe with no signs of slowing down, and a similar trend in New Zealand is quickly developing. This validates our strategy to invest in this area," he says.

"Receiving this Licence to Manufacture Medicines is the culmination of a multi-year process. It creates a competitive advantage for Cannasouth because it enables us to produce our medicinal cannabis
products in-house without relying on third-party manufacturing steps."

Cannasouth's GMP Licence to Manufacture Medicines covers all post-harvest activities and is additional to the Good Agricultural and Collection Practice (GACP) quality standard previously achieved.

Cannasouth shareholders recently approved the proposed merger with Bay of Plenty-based Eqalis. On completion of the merger, Cannasouth will operate with end-to-end GMP approval to produce dried cannabis flower through to the manufacture of cannabis-based ingredients and medicinal cannabis products, including oral solutions.

Now that a Licence to Manufacture Medicines has been obtained, Cannasouth will commence the process of verifying flower products for the New Zealand market, creating more competition to benefit
New Zealand patients.

Mr. Lucas says, "This is a major achievement, and I would like to thank our people for making this happen and our shareholders for their support along the way."

For more information:

Publication date:

Receive the daily newsletter in your email for free | Click here

Other news in this sector:

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.

Click here for a guide on disabling your adblocker.